Andrew Dunn is a biopharma correspondent, focused on uncovering and explaining the future of the biotech and pharmaceutical industries. He joined Endpoints News in 2023, most recently working as a senior healthcare reporter at Business Insider. He previously worked as a reporter at BioPharma Dive, and his reporting has been cited by news outlets including the Washington Post, CNN, and the New York Times. He’s also appeared on CNBC, C-SPAN, and MSNBC to discuss his work. He graduated from the University of Maryland, College Park, majoring in journalism and economics, and lives in Washington, DC.
